Meeting
2019 ASCO Annual Meeting
Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.
Authors
Salma K. Jabbour
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Salma K. Jabbour , Abigail T. Berman , Roy H. Decker , Yong Lin , Steven J. Feigenberg , Scott N. Gettinger , Charu Aggarwal , Corey J. Langer , Charles B. Simone II, Jeffrey D. Bradley , Joseph Aisner , Jyoti Malhotra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02621398
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8511)
DOI
10.1200/JCO.2019.37.15_suppl.8511
Abstract #
8511
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
First Author: Martin Reck
Poster
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
First Author: Salma K. Jabbour
Poster
2020 ASCO Virtual Scientific Program
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
First Author: Helen J. Ross